Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)

ClinicalTrials.gov ID: NCT07901751

Public ClinicalTrials.gov record NCT07901751. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2/3, Double-masked, Randomized, Sham-controlled, Single Dose Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical trial is to evaluate the effectiveness and safety of a single injection into the eye of an investigational gene therapy in participants with retinitis pigmentosa (RP).

Study identification

NCT ID: NCT07901751
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Ray Therapeutics, Inc.; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Interventions

RTx-015 Drug
Sham Control Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2026 (Estimated)
Primary completion: Oct 2028 (Estimated)
Completion: Oct 2028 (Estimated)
Last update posted: Oct 28, 2026

2026 – 2028

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
RayTx Clinical Site	Phoenix	Arizona	85020	Not yet recruiting
RayTx Clinical Site	Bakersfield	California	93309	Recruiting
RayTx Clinical Site	Beverly Hills	California	90211	Recruiting
RayTx Clinical Site	Santa Barbara	California	93103	Not yet recruiting
RayTx Clinical Site	Deerfield Beach	Florida	33064	Not yet recruiting
RayTx Clinical Site	‘Aiea	Hawaii	96701	Not yet recruiting
RayTx Clinical Site	Oak Park	Illinois	60304	Recruiting
RayTx Clinical Site	Detroit	Michigan	48201	Not yet recruiting
RayTx Clinical Site	Edina	Minnesota	55435	Not yet recruiting
RayTx Clinical Site	Bloomfield	New Jersey	07003	Not yet recruiting
RayTx Clinical Site	Greensboro	North Carolina	27401	Recruiting
RayTx Clinical Site	Portland	Oregon	97225	Recruiting
RayTx Clinical Site	Mt. Pleasant	South Carolina	29464	Recruiting
RayTx Clinical Site	San Antonio	Texas	78240	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07901751, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 28, 2026 · Synced Oct 28, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07901751 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →